CSE Bulletin: Suspensions - AION, CALI.X, LITS, NIRV

CSE Bulletin: Suspensions - AION, CALI.X, LITS, NIRV

Le 5 septembreSeptember 2025)Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.

For more information about Cease Trade Orders, visit the Canadian Securities Administrators Cease Trade Order database at www.securities-administrators.ca.

_________________________________

En vigueur immédiatement, les sociétés suivantes sont suspendues conformément à la politique 3 du CSE. Les suspensions sont considérées comme des arrêts réglementaires au sens du Règlement 23-101 sur les règles de négociation. Un ordre d'interdiction d'opérations a été émis par une ou plusieurs commissions des valeurs mobilières.

Pour en savoir plus sur les ordonnances d'interdiction d'opérations, visitez la base de données des ordonnances d'interdiction d'opérations des Autorités canadiennes en valeurs mobilières à www.securities-administrators.ca.

Company Name/

Nom de la compagnie :

Symbol/

Symbole :

Securities Commission/Commission des Valeurs Mobilières

Aion Therapeutic Inc.

AION

British Columbia Securities Commission

FinCanna Capital Corp. CALI.X British Columbia Securities Commission

LiTHOS Group Ltd.

LITS

British Columbia Securities Commission

Nirvana Life Sciences Inc.

NIRV

British Columbia Securities Commission

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Si vous avez des questions ou si vous avez besoin d'informations supplémentaires, veuillez contacter le service des inscriptions au 416 367-7340 ou par courriel l'adresse: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

AION:CNX
The Conversation (0)
Aion Therapeutics

Aion Therapeutics

Overview

Clinical laboratory research studies have clearly demonstrated that medical cannabis and medicinal mushrooms work together in symbiotic ways to promote healing. Aion Therapeutic (CSE: AION) elevates these findings by applying artificial intelligence (AI) techniques to create disease specific patentable medical cannabis/mushroom formulations, specifically designed for individual patients. This represents a historic breakthrough, bringing medical cannabis and medicinal mushrooms treatments into the realm of true personalized medicine.

Aion Therapeutic is a unique international pharmaceutical company specializing in blending the natural healing powers of medical cannabis and medicinal mushroom compounds to deliver a revolutionary new class of personalized therapeutics. In addition, with the recent opening of the new Aion International Center for Psychedelic Psychiatry, Aion leads the world in specialized use of psilocybin for the treatment of addiction and major depressive disorder (MDD).

Keep reading...Show less

Niche Cannabis Extraction in British Columbia

Latest Press Releases

Related News

×